New Hope for Rare Cancer as TEVIMBRA Nears Canadian Funding

TORONTO, ON – May 28, 2026 – Patients with a rare and aggressive form of head and neck cancer are a significant step closer to accessing a new standard of care, as Canadian health authorities have given a crucial green light to the immunotherapy drug TEVIMBRA. Oncology company BeOne Medicines announced today that both Canada's Drug Agency (CDA-AMC) and Quebec's Institut national d'excellence en santé et en services sociaux (INESSS) have issued positive reimbursement recommendations for the drug.

The recommendations are for TEVIMBRA (tislelizumab) to be used in combination with chemotherapy for the first-line treatment of adult patients with recurrent or metastatic nasopharyngeal carcinoma (NPC). This development follows Health Canada's approval of the drug in December 2025 and addresses a long-standing gap in care, as there is currently no publicly funded first-line immunotherapy option for this specific condition in the country.

For a small but vulnerable patient population, this marks a pivotal moment. The positive assessments from these key health technology assessment (HTA) bodies signal that the treatment's clinical value is recognized, paving the way for negotiations with provincial and territorial governments to have the drug added to public formularies.

A Critical Unmet Need in a Rare Cancer

Nasopharyngeal carcinoma is a cancer that begins in the upper part of the throat, behind the nose. Its deep anatomical location and often mild early symptoms mean it is frequently diagnosed at an advanced, metastatic stage, making it particularly challenging to treat. While considered rare in the general Canadian population, with an incidence below 1 per 100,000, its impact is not uniform. The disease occurs at a significantly higher rate in certain populations, including Inuit communities in Nunavut and the Northwest Territories, where incidence can be as high as 10 per 100,000.

For years, clinicians and patients have navigated a landscape with few effective options. One oncologist specializing in head and neck cancers noted that adult patients with recurrent or metastatic NPC have "long faced limited therapeutic choices," with standard chemotherapy offering only short-term benefits. The advent of immunotherapy has changed the paradigm for many cancers, but access has remained a hurdle for rare diseases like NPC.

The recommendations for TEVIMBRA are based on the strength of the RATIONALE-309 Phase 3 clinical trial. The study demonstrated that adding TEVIMBRA to a standard chemotherapy regimen of gemcitabine and cisplatin resulted in a significant and clinically meaningful improvement in progression-free survival compared to chemotherapy alone. Recently published three-year follow-up data further reinforced the drug's long-term efficacy and safety profile.

Navigating Canada's Complex Reimbursement Pathway

The positive nods from CDA-AMC and INESSS are a major victory in Canada's notoriously complex drug funding process. These agencies are responsible for evaluating the clinical and economic evidence of new drugs to advise public payers. Their endorsement is the essential key that unlocks negotiations with individual provinces, which ultimately decide what their public drug plans will cover.

Interestingly, TEVIMBRA is not the only new immunotherapy approved for NPC. Health Canada previously approved a competing drug, toripalimab, in October 2025, making it the first immunotherapy regulatorily approved for the condition. However, BeOne Medicines' success in securing positive reimbursement recommendations from HTA bodies positions TEVIMBRA to potentially become the first publicly funded first-line immunotherapy option, a critical distinction for patient access.

"These positive recommendations from CDA-AMC and INESSS represent an important milestone in the Canadian reimbursement pathway," said Kristian Stubbs, General Manager for Canada at BeOne Medicines, in a statement. "We will continue to work collaboratively with provincial governments and other stakeholders to help bring this important treatment option to eligible patients across Canada."

The Policy and Price of Innovation

The path for innovative but expensive drugs for rare diseases is being smoothed by new national policies. The decision on TEVIMBRA comes as the federal government's National Strategy for Drugs for Rare Diseases, launched in March 2023, begins to take effect. The strategy allocated $1.5 billion over three years to improve access, with $1.4 billion flowing directly to provinces and territories through bilateral agreements to help them fund new and effective treatments.

With a per-vial cost of $3,080.00, a single 21-day treatment cycle of TEVIMBRA costs approximately $6,160, making public funding essential for equitable access. The recommendation to fund it, despite the high price tag, underscores a policy shift towards accommodating high-value treatments for diseases with small patient populations and significant unmet needs. This decision serves as a tangible example of the national strategy in action, balancing public healthcare budgets with the urgent need for medical innovation.

A Strategic Milestone for BeOne Medicines

For BeOne Medicines, this achievement is more than just a single-market success; it is a significant strategic win. The company, which recently rebranded from BeiGene and redomiciled to Switzerland to reflect its global focus, is a major player in the oncology space. With a NASDAQ listing (ONC), a market capitalization exceeding $30 billion, and global revenues of $5.3 billion in 2025, BeOne is a formidable force.

Achieving this reimbursement milestone in Canada demonstrates the company's ability to successfully navigate sophisticated and stringent HTA processes in key Western markets. While the Canadian market for a rare cancer like NPC will not dramatically alter the company's bottom line, it solidifies TEVIMBRA's clinical and commercial profile globally. It also reinforces BeOne's commitment to its broad oncology portfolio, which spans from blockbuster drugs to targeted therapies for rare conditions.

The next and final step is for BeOne to successfully negotiate listing agreements with each of Canada's provincial and territorial drug plans. While timelines can vary, the strong, unified recommendation from the country's top assessment bodies provides a clear and powerful mandate to move forward, offering tangible hope to patients and clinicians who have long awaited such a breakthrough.